Excipient database: all systems go as US FDA clears backlog
The US FDA has almost cleared a backlog of 4000 excipient formulations in its Inactive Ingredient Database (IID) and wants drugmakers to help ensure ongoing accuracy.
The US FDA has almost cleared a backlog of 4000 excipient formulations in its Inactive Ingredient Database (IID) and wants drugmakers to help ensure ongoing accuracy.
The IID is intended to be a definitive searchable catalogue of every excipient that has ever been used in a US Food and Drug Administration (FDA) approved drug. The database can be cited by drugmakers to help reduce the length of review for a new product which contains a catalogued excipient.